Identification of Innovative Biomarkers to Predict Outcomes in Hepatocellular Carcinoma Treated With Tremelimumab and Durvalumab
Latest Information Update: 11 Apr 2025
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms PREDICT-HCC
- 11 Apr 2025 New trial record